Proton-pump inhibitor-responsive esophageal eosinophilia

Javier Molina-Infante, David A Katzka

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) refers to patients showing symptoms and histological findings suggestive of eosinophilic esophagitis (EoE) who achieve complete remission on PPI therapy. This article aims to review evolving evidence on this novel phenotype over the last year. RECENT FINDINGS: Several prospective series have reported consistent rates of PPI-REE (30-40%) in adults with suspected EoE. At baseline, PPI-REE and EoE have been shown to be indistinguishable upon clinical, endoscopic, and molecular characteristics [eotaxin-3, interleukin (IL-5), and IL-13 expression]. PPI therapy partially restores esophageal mucosal integrity in PPI-REE, but not in EoE. Anti-inflammatory effects of PPI therapy, independent of acid suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures. PPI therapy in vivo downregulates Th2 cytokines in PPI-REE patients, in a similar fashion to that seen in steroid-responsive EoE. SUMMARY: PPI-REE has emerged as a common clinical phenotype. PPI-REE and EoE remain largely indistinguishable, suggesting that they might be the same disease at baseline. While PPI therapy has been demonstrated to partially restore epithelial integrity in PPI-REE, in-vitro and in-vivo studies suggest that the anti-inflammatory effects of PPI therapy may be responsible for this restoration through inhibition of the Th2-allergic pathway rather than only acid suppression.

Original languageEnglish (US)
Pages (from-to)428-433
Number of pages6
JournalCurrent Opinion in Gastroenterology
Volume30
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Eosinophilic Esophagitis
Proton Pump Inhibitors
Eosinophilia
Interleukin-5
Anti-Inflammatory Agents
Therapeutics
Phenotype
Acids
Interleukin-13
Gastroesophageal Reflux
Down-Regulation
Cell Culture Techniques
Steroids
Cytokines

Keywords

  • Eosinophilic esophagitis
  • Gastroesophageal reflux disease
  • Proton-pump inhibitor-responsive esophageal eosinophilia

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Proton-pump inhibitor-responsive esophageal eosinophilia. / Molina-Infante, Javier; Katzka, David A.

In: Current Opinion in Gastroenterology, Vol. 30, No. 4, 2014, p. 428-433.

Research output: Contribution to journalArticle

@article{540216ce6fe0455d98b08c51dc133bf1,
title = "Proton-pump inhibitor-responsive esophageal eosinophilia",
abstract = "PURPOSE OF REVIEW: Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) refers to patients showing symptoms and histological findings suggestive of eosinophilic esophagitis (EoE) who achieve complete remission on PPI therapy. This article aims to review evolving evidence on this novel phenotype over the last year. RECENT FINDINGS: Several prospective series have reported consistent rates of PPI-REE (30-40{\%}) in adults with suspected EoE. At baseline, PPI-REE and EoE have been shown to be indistinguishable upon clinical, endoscopic, and molecular characteristics [eotaxin-3, interleukin (IL-5), and IL-13 expression]. PPI therapy partially restores esophageal mucosal integrity in PPI-REE, but not in EoE. Anti-inflammatory effects of PPI therapy, independent of acid suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures. PPI therapy in vivo downregulates Th2 cytokines in PPI-REE patients, in a similar fashion to that seen in steroid-responsive EoE. SUMMARY: PPI-REE has emerged as a common clinical phenotype. PPI-REE and EoE remain largely indistinguishable, suggesting that they might be the same disease at baseline. While PPI therapy has been demonstrated to partially restore epithelial integrity in PPI-REE, in-vitro and in-vivo studies suggest that the anti-inflammatory effects of PPI therapy may be responsible for this restoration through inhibition of the Th2-allergic pathway rather than only acid suppression.",
keywords = "Eosinophilic esophagitis, Gastroesophageal reflux disease, Proton-pump inhibitor-responsive esophageal eosinophilia",
author = "Javier Molina-Infante and Katzka, {David A}",
year = "2014",
doi = "10.1097/MOG.0000000000000080",
language = "English (US)",
volume = "30",
pages = "428--433",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Proton-pump inhibitor-responsive esophageal eosinophilia

AU - Molina-Infante, Javier

AU - Katzka, David A

PY - 2014

Y1 - 2014

N2 - PURPOSE OF REVIEW: Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) refers to patients showing symptoms and histological findings suggestive of eosinophilic esophagitis (EoE) who achieve complete remission on PPI therapy. This article aims to review evolving evidence on this novel phenotype over the last year. RECENT FINDINGS: Several prospective series have reported consistent rates of PPI-REE (30-40%) in adults with suspected EoE. At baseline, PPI-REE and EoE have been shown to be indistinguishable upon clinical, endoscopic, and molecular characteristics [eotaxin-3, interleukin (IL-5), and IL-13 expression]. PPI therapy partially restores esophageal mucosal integrity in PPI-REE, but not in EoE. Anti-inflammatory effects of PPI therapy, independent of acid suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures. PPI therapy in vivo downregulates Th2 cytokines in PPI-REE patients, in a similar fashion to that seen in steroid-responsive EoE. SUMMARY: PPI-REE has emerged as a common clinical phenotype. PPI-REE and EoE remain largely indistinguishable, suggesting that they might be the same disease at baseline. While PPI therapy has been demonstrated to partially restore epithelial integrity in PPI-REE, in-vitro and in-vivo studies suggest that the anti-inflammatory effects of PPI therapy may be responsible for this restoration through inhibition of the Th2-allergic pathway rather than only acid suppression.

AB - PURPOSE OF REVIEW: Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) refers to patients showing symptoms and histological findings suggestive of eosinophilic esophagitis (EoE) who achieve complete remission on PPI therapy. This article aims to review evolving evidence on this novel phenotype over the last year. RECENT FINDINGS: Several prospective series have reported consistent rates of PPI-REE (30-40%) in adults with suspected EoE. At baseline, PPI-REE and EoE have been shown to be indistinguishable upon clinical, endoscopic, and molecular characteristics [eotaxin-3, interleukin (IL-5), and IL-13 expression]. PPI therapy partially restores esophageal mucosal integrity in PPI-REE, but not in EoE. Anti-inflammatory effects of PPI therapy, independent of acid suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures. PPI therapy in vivo downregulates Th2 cytokines in PPI-REE patients, in a similar fashion to that seen in steroid-responsive EoE. SUMMARY: PPI-REE has emerged as a common clinical phenotype. PPI-REE and EoE remain largely indistinguishable, suggesting that they might be the same disease at baseline. While PPI therapy has been demonstrated to partially restore epithelial integrity in PPI-REE, in-vitro and in-vivo studies suggest that the anti-inflammatory effects of PPI therapy may be responsible for this restoration through inhibition of the Th2-allergic pathway rather than only acid suppression.

KW - Eosinophilic esophagitis

KW - Gastroesophageal reflux disease

KW - Proton-pump inhibitor-responsive esophageal eosinophilia

UR - http://www.scopus.com/inward/record.url?scp=84902264299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902264299&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000080

DO - 10.1097/MOG.0000000000000080

M3 - Article

C2 - 24837227

AN - SCOPUS:84902264299

VL - 30

SP - 428

EP - 433

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 4

ER -